SRR13780251
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.540
- E2F_TARGETS+0.490
- MYC_TARGETS_V1+0.400
- G2M_CHECKPOINT+0.330
- DNA_REPAIR+0.260
- SPERMATOGENESIS+0.260
- HEDGEHOG_SIGNALING+0.250
- KRAS_SIGNALING_DN+0.150
- UV_RESPONSE_UP+0.120
- MYC_TARGETS_V2+0.090
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.630
- INTERFERON_GAMMA_RESPONSE-0.590
- IL6_JAK_STAT3_SIGNALING-0.560
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- INFLAMMATORY_RESPONSE-0.400
- ALLOGRAFT_REJECTION-0.390
- NOTCH_SIGNALING-0.390
- IL2_STAT5_SIGNALING-0.380
- TGF_BETA_SIGNALING-0.380
- ANGIOGENESIS-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_WH5HDE0A | medulloblastoma | — | 0.943 |
| 2 | BS_S69QZAJR | medulloblastoma | — | 0.934 |
| 3 | SRR1797262 | — | cohortSC | 0.932 |
| 4 | BS_QWNBZ9RJ | Embryonal tumors | — | 0.924 |
| 5 | TCGA-C4-A0EZ-01A-21R-A24X-07 | — | — | 0.924 |
| 6 | BS_ZXYDSBM9 | medulloblastoma | — | 0.915 |
| 7 | BS_AM70R8RG | medulloblastoma | — | 0.915 |
| 8 | BS_FCAKKZ20 | medulloblastoma | — | 0.914 |
| 9 | SRR13780269 | — | cohortSC | 0.908 |
| 10 | 91648 | EPN | Supratentorial EPN | 0.904 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.540 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.400 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.090 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.080 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.070 | Inavolisib | — uncovered |